Evercore ISI downgraded Bellus Health (BLU) to In Line from Outperform with a price target of $14.75, down from $24, after the company agreed to a deal to be acquired by GSK (GSK).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BLU: